

Atara Biotherapeutics, Inc.
Form 8-K
February 10, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2017

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction

of Incorporation)

001-36548
(Commission

File Number)

46-0920988
(IRS Employer

Identification No.)

701 Gateway Boulevard, Suite 200

South San Francisco, CA
(Address of Principal Executive Offices)

94080
(Zip Code)

Registrant's Telephone Number, Including Area Code: (415) 287-2410

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 6, 2017, the Compensation Committee (the *Committee*) of the Board of Directors of Atara Biotherapeutics, Inc. (the *Company*) approved discretionary cash bonus payments to its principal executive officer and named executive officers in recognition of the Company's performance during 2016 as set forth in the table below:

Name	Title	Bonus
Isaac Ciechanover	Chief Executive Officer	\$ 270,270
Christopher Haqq	Executive Vice President, Chief Scientific Officer	\$ 154,752
Heather Turner	Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy	\$ 127,592

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Atara Biotherapeutics, Inc.

By: /s/ John McGrath
John McGrath

Chief Financial Officer

Date: February 10, 2017